Dewpoint Therapeutics Inc. has nominated a second development candidate, DPTX-3496. The oral, small-molecule condensate modulator targets β-catenin to address Wnt-driven colorectal cancer, ...
The platform's success with β-catenin, a key player in cancer development, demonstrates its potential to revolutionize drug discovery for previously intractable targets. The Wnt/β-catenin ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback